Allan JN et al. Primary analysis of the fixed-duration cohort from the phase 2 CAPTIVATE study of first-line ibrutinib + venetoclax for chronic lymphocytic leukemia/small lymphocytic lymphoma. EHA 2021;Abstract S147.
Byrd JC et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. ASCO 2021;Abstract 7500.
Carlo-Stella C et al. Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts). ASCO 2021;Abstract 7519.
Clausen MR et al. Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity. ASCO 2021;Abstract 7518.
Eichhorst B et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021;32(1):23-33. Abstract
Fischer K et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 2019;380(23):2225-36. Abstract
Fowler NH et al. Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol 2021;39(15):1609-18. Abstract
Harrup R et al. Efficacy of subsequent novel targeted therapies, including repeated venetoclax-rituximab (VenR), in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) previously treated with fixed-duration VenR in the MURANO study. ASH 2020;Abstract 3139.
Hillmen P et al. First interim analysis of ALPINE study: Results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. EHA 2021;Abstract LB1900.
Kater A et al. Fixed-duration ibrutinib and venetoclax (I+V) versus chlorambucil plus obinutuzumab (CLB+O) for first-line (1L) chronic lymphocytic leukemia (CLL): Primary analysis of the phase 3 GLOW study. EHA 2021;Abstract LB1902.
Matasar MJ et al. Copanlisib + rituximab versus rituximab + placebo in patients with relapsed follicular (FL) or marginal zone lymphoma (MZL): Subset analysis from the phase III CHRONOS-3 trial. ASCO 2021;Abstract 7510.
Roeker LE et al. Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice. Clin Cancer Res 2019;25(14):4264-70. Abstract
Siddiqi T et al. Updated follow-up of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma treated with lisocabtagene maraleucel in the phase 1 monotherapy cohort of Transcend CLL 004, including high-risk and ibrutinib-treated patients. ASH 2020;Abstract 546.
Thompson MC et al. Venetoclax re-treatment of chronic lymphocytic leukemia (CLL) patients after a previous venetoclax-based regimen. ASH 2020;Abstract 3136.
Wierda WG et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 4.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020;18(2):185-217. Abstract
Wierda WG et al. Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 1-year disease-free survival (DFS) results from the MRD cohort of the phase 2 CAPTIVATE study trial. ASH 2020;Abstract 123.